热门资讯> 正文
ANI Pharma购买与Iluvien和Yutiq相关的版税
2025-03-18 19:46
- ANI Pharmaceuticals (NASDAQ:ANIP) announced Tuesday it has completed the purchase of royalty obligations linked to Iluvien and Yutiq, two eye disease therapies the company added with its $5.50 per share acquisition of Alimera Sciences in 2024.
- Accordingly, ANI Pharmaceuticals (NASDAQ:ANIP) will not be required to pay the 3.125% perpetual royalties based on Iluvien and Yutiq global revenues to SWK Funding LLC with effect from Jan. 1, 2025.
- The company has made a one-time payment of $17.25M using its cash on hand to complete the transaction.
- With its Q4 2024 financials, ANIP said it has made substantial progress toward ensuring supply security for Iluvien and Yutiq, which it expects could generate $97M-$103M in net revenue in 2025 compared to $32M last year.
More on ANI Pharmaceuticals
- ANI Pharmaceuticals, Inc. (ANIP) Q4 2024 Earnings Call Transcript
- ANI Pharmaceuticals: More Than Just A Generics Company
- ANI Pharma wins Overweight rating at J.P. Morgan on growth prospects
- ANI Pharmaceuticals beats top-line and bottom-line estimates; updates FY25 outlook
- Seeking Alpha’s Quant Rating on ANI Pharmaceuticals
推荐文章
华盛早报丨黑天鹅来袭？特朗普掀起人事震动，美国对等关税生效在即；小米汽车7月交付量超3万辆
一周财经日历 | 特朗普对等关税将于8月7日生效；Palantir、超微电脑等财报来袭
8月金股抢先睇！港股能否继续抽升？哪些赛道值得关注
英诺赛科午前飙升逾31% 英伟达最新800V架构供应商名单曝光公司为中国唯一入选芯片企业
特朗普官宣“对等关税”：各国税率10%至41%不等 加拿大上调至35%
盘后大跌6%！亚马逊交出优秀财报 但云业务仍逊色于微软谷歌
苹果第三财季营收940.36亿美元 净利润同比增长9%
外盘头条：白宫称特朗普将在午夜前设定新关税 苹果季度营收远超预期 Pimco青睐短至中期欧洲债券
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
